Physician profile
Michele C Allan
NPI 1801061189
$1,642.73
in general payments reported to CMS, 2019-2025
13 companies · $282 in 2025
The $282 reported for 2025 was more than what 82% of Women'S Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $499 · 2023: $354 · 2024: $294 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.43 |
| Education | $106.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $493.69 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $370.64 | 2021-2023 | |
| Myovant Sciences INC. | $136.78 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $130.02 | 2023-2025 | |
| Exeltis, USA INC. | $129.90 | 2021-2024 | Slynd |
| Amgen INC. | $118.39 | 2023 | Prolia |
| Merck Sharp & Dohme LLC | $91.06 | 2021-2023 | Gardasil 9 |
| Scynexis, INC. | $49.28 | 2022 | |
| Pfizer INC. | $39.84 | 2021-2022 | |
| Therapeuticsmd, INC. | $31.25 | 2021 | |
| Sumitomo Pharma America, INC. | $21.26 | 2024 | Myfembree |
| Millicent US INC | $17.38 | 2024 | Intrarosa |
| Coopersurgical, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Allan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.